Halozyme Therapeutics (HALO) Revenue (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Revenue data on file, last reported at $376.7 million in Q1 2026.

• Revenue for Q1 2026 came in at $376.7 million, up 42.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 39.12% YoY), and the FY2025 annual result was $1.4 billion, up 37.55% from the prior year.
• Revenue declined to $376.7 million in Q1 2026 per HALO's latest filing, from $451.8 million in the prior quarter.
• Over five years, Revenue peaked at $451.8 million in Q4 2025 and troughed at $117.3 million in Q1 2022.
• A 5-year average of $251.6 million and a median of $230.0 million in 2023 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2023: Revenue surged 80.42% in 2022, then advanced 3.38% in 2023.
• A 5-year view of Revenue shows it stood at $181.5 million in 2022, then advanced by 26.75% to $230.0 million in 2023, then gained by 29.55% to $298.0 million in 2024, then surged by 51.6% to $451.8 million in 2025, then slipped by 16.61% to $376.7 million in 2026.
• Business Quant data shows HALO's Revenue at $376.7 million in Q1 2026, $451.8 million in Q4 2025, and $354.3 million in Q3 2025.